- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01625169
Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
Antiretroviral Drug Concentrations and HIV Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART (Highly Active Antiretroviral Therapy) Therapy: Etravirine (ETR) Pharmacokinetics (PK) in Breast Milk and Plasma
HIV positive pregnant women who receive potent combination antiretroviral therapy over at least the last trimester of pregnancy, and who have proper obstetric interventions and are able to avoid breast feeding, decrease the risk of having an infected infant to about 1%. Breast milk HIV-1 RNA (cell free) viral load is significantly associated with breast milk transmission, and a 2-fold increased risk of transmission associated with every 10-fold increase in breast milk viral load has been reported. In addition, cell associated virus (HIV DNA) was associated with a significant increase in risk of transmission independent of the level of cell-free viral RNA.
However, multiple studies of HIV positive women giving birth have shown that exclusive breast-feeding carries a much lower risk of HIV transmission than mixed breast-feeding (defined as breast milk along with complementary food, other milk, and/or infant formula). The proposed study will measure the antiretroviral (ARV) drug etravirine concentrations in blood and breast milk in postpartum HIV positive women on HAART therapy. The short-term goal is to determine how much etravirine penetrates into breast milk, and whether it leads to undetectable HIV viral load in the breast milk and therefore has the potential to decrease the risk of transmission of HIV through breast milk. The long term goal is to see if breast milk HIV levels can be lowered sufficiently to prevent maternal to child transmission (MTCT) of HIV in infants receiving only breast feeding in resource poor areas.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90033
- LAC+USC MCA Clinic
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- HIV+ pregnant women on HAART for the prevention of MTCT w/ undetectable viral load at time of delivery (w/i 30 days of delivery).
- 18 years and older
- Only women who are deemed by the physician as being capable of understanding that HIV positive women should not breastfeed will be approached.
- Life expectancy greater than 6 months
- No known allergies to etravirine
- Willingness of subject to adhere to protocol requirements.
Exclusion Criteria:
- Pregnant women with medical or psychological contraindications to breast milk expression.
Requirements for prohibited medications:
- ARV: Tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, and protease inhibitors administered without ritonavir, nonnucleoside reverse transcriptase inhibitor (NNRTIs).
- Alternative/CAM: St. John's wort
- Anticonvulsants: Phenobarbital, carbamazepine , phenytoin
- Anti-infectives: Rifampin
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: HIV + pregnant women
Etravirine pharmacokinetics in breast milk and plasma.
Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
|
HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum.
PK will be done on postpartum days 5 and 14.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Peak Plasma Concentration of Etravirine in Plasma
Tidsramme: Day 5
|
Cmax ng/ml Note: One participant did not complete the Day 5 evaluation. |
Day 5
|
Peak Concentration of Etravirine in Breast Milk
Tidsramme: day 5
|
Cmax ng/ml Note: One participant did not complete the Day 5 evaluation. |
day 5
|
Peak Concentration of Etravirine in Breast Milk
Tidsramme: day 14
|
Cmax ng/mL
|
day 14
|
Peak Plasma Concentration of Etravirine in Plasma
Tidsramme: day 14
|
Cmax ng/mL
|
day 14
|
Area Under the Curve (AUC) 0-12 for Plasma
Tidsramme: Day 5: 0, 2,4, 8 and 24 hours post dose
|
AUC 0-12 ng*hr/ml
|
Day 5: 0, 2,4, 8 and 24 hours post dose
|
Area Under the Curve (AUC) 0-12 for Plasma
Tidsramme: Day 14: 0, 2,4, 8 and 24 hours post dose
|
AUC 0-12 ng*hr/ml
|
Day 14: 0, 2,4, 8 and 24 hours post dose
|
Area Under the Curve (AUC) 0-12 for Breast Milk
Tidsramme: Day 5
|
AUC 0-12 ng*hr/ml
|
Day 5
|
Area Under the Curve (AUC) 0-12 for Breast Milk
Tidsramme: Day 14
|
AUC 0-12 ng*hr/ml
|
Day 14
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
HIV Viral Load in Breast Milk and Plasma
Tidsramme: Day 5
|
Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml
|
Day 5
|
HIV Viral Load in Breast Milk and Plasma
Tidsramme: Day 14
|
Positive HIV RNA in breast milk and plasma- LDL 40 copies/ml
|
Day 14
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: LaShonda Y Spencer, MD, University of Southern California
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HS-09-00698
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutteringHIV | HIV-testing | HIV-kobling til omsorg | HIV-behandlingForente stater
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationFullførtPartner HIV-testing | Par HIV-rådgivning | Parkommunikasjon | HIV-forekomstKamerun, Den dominikanske republikk, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement og andre samarbeidspartnereUkjentHIV | HIV-uinfiserte barn | Barn utsatt for HIVKamerun
-
University of MinnesotaTilbaketrukketHIV-infeksjoner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS og infeksjonerForente stater
-
CDC FoundationGilead SciencesUkjentHIV-preeksponeringsprofylakse | HIV kjemoprofylakseForente stater
-
Hospital Clinic of BarcelonaFullførtIntegrasehemmere, HIV; HIV PROTEASE HEMMINGSpania
-
Erasmus Medical CenterHar ikke rekruttert ennåHIV-infeksjoner | Hiv | HIV-1-infeksjon | HIV I infeksjonNederland
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London og andre samarbeidspartnereRekrutteringHIV | HIV-testing | Kobling til omsorgSør-Afrika
-
University of WashingtonNational Institute of Mental Health (NIMH)RekrutteringHIV-forebygging | HIV-preeksponeringsprofylakse | GjennomføringKenya
-
University of Maryland, BaltimoreTilbaketrukketHiv | Nyretransplantasjon | HIV-reservoar | CCR5Forente stater
Kliniske studier på Etravirine pharmacokinetics in breast milk and plasma
-
Sultan Abdulhamid Han Training and Research Hospital...Har ikke rekruttert ennåBrystkreft | Dysfunksjon i øvre ekstremiteter | VevsvedheftTyrkia